Global Blood Therapeutics (NASDAQ:GBT) had its target price upped by analysts at SunTrust Banks to $90.00 in a report released on Tuesday, The Fly reports. The firm presently has a “positive” rating on the stock. SunTrust Banks’ price objective suggests a potential upside of 98.02% from the stock’s current price. SunTrust Banks also issued estimates for Global Blood Therapeutics’ FY2018 earnings at ($3.45) EPS, FY2020 earnings at ($3.41) EPS, FY2021 earnings at ($2.32) EPS and FY2022 earnings at ($0.23) EPS.
A number of other equities research analysts also recently issued reports on the company. HC Wainwright set a $150.00 price target on Global Blood Therapeutics and gave the company a “buy” rating in a research note on Tuesday. William Blair restated a “buy” rating on shares of Global Blood Therapeutics in a research note on Monday. Cantor Fitzgerald set a $96.00 price target on Global Blood Therapeutics and gave the company a “buy” rating in a research note on Monday. Oppenheimer set a $82.00 price target on Global Blood Therapeutics and gave the company a “buy” rating in a research note on Monday. Finally, BidaskClub downgraded Global Blood Therapeutics from a “sell” rating to a “strong sell” rating in a research note on Friday, November 30th. One analyst has rated the stock with a sell rating, two have given a hold rating and fourteen have assigned a buy rating to the stock. Global Blood Therapeutics presently has a consensus rating of “Buy” and an average target price of $83.20.
NASDAQ GBT opened at $45.45 on Tuesday. Global Blood Therapeutics has a one year low of $30.15 and a one year high of $68.05. The stock has a market capitalization of $2.37 billion, a P/E ratio of -16.47 and a beta of 3.65.
Several hedge funds have recently bought and sold shares of GBT. FMR LLC lifted its holdings in Global Blood Therapeutics by 21.0% in the 3rd quarter. FMR LLC now owns 7,807,836 shares of the company’s stock worth $296,698,000 after purchasing an additional 1,357,642 shares in the last quarter. BlackRock Inc. lifted its holdings in Global Blood Therapeutics by 27.7% in the 2nd quarter. BlackRock Inc. now owns 4,142,762 shares of the company’s stock worth $187,252,000 after purchasing an additional 898,162 shares in the last quarter. PointState Capital LP purchased a new position in Global Blood Therapeutics in the 3rd quarter worth approximately $20,832,000. Janus Henderson Group PLC lifted its holdings in Global Blood Therapeutics by 12.2% in the 2nd quarter. Janus Henderson Group PLC now owns 4,154,385 shares of the company’s stock worth $187,778,000 after purchasing an additional 452,843 shares in the last quarter. Finally, Perceptive Advisors LLC lifted its holdings in Global Blood Therapeutics by 6.6% in the 3rd quarter. Perceptive Advisors LLC now owns 5,148,910 shares of the company’s stock worth $195,658,000 after purchasing an additional 320,000 shares in the last quarter.
About Global Blood Therapeutics
Global Blood Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the discovery, development, and delivery of treatments for underserved patient communities. It is developing its lead product candidate, voxelotor, an oral, once-daily therapy for sickle cell disease (SCD). The company is evaluating voxelotor in SCD in a Phase III clinical trial in adult and adolescent patients with SCD.
See Also: Ex-Dividend
Receive News & Ratings for Global Blood Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Global Blood Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.